Senores Pharmaceuticals Ltd. · NSE:SENORES
Senores Pharmaceuticals — Q3 FY25 Earnings Presentation
34 slides from Senores Pharmaceuticals's earnings presentation, Jan 23, 2025
Slide 1: Intimation to stock exchanges – Investor Presentation
Date: January 23, 2025 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400001 Bandra (E), Mumbai – 400 051 BSE
Slide 2: Investor Presentation January 2025
Investor Presentation JANUARY 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Senores Pharmaceuticals Limited (the “Company” / “SPL”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscri
Slide 4: Financial Highlights Q3 and 9M FY25
Financial Highlights Q3 and 9M FY25 Private & Confidential
Slide 5: Q3 & 9M FY25 Business Segment Financial Highlights
Q3 & 9M FY25 Business Segment Financial Highlights* Regulated Markets Emerging Markets Others (API, Injectables) +1,164.8% +99.8% +25.6% Revenue (INR Crs) 180.5 84.6 18.9 +289.3% 15.0 +2.5% +90.6% 90.4 68.4 70.2 6.8 26.1 3.6 6.7 6.7 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q3 FY25 9M FY24 9M FY25 Q3
Slide 6: Q3 FY25 Key Operational Highlights
Q3 FY25 Key Operational Highlights Regulated Markets Emerging Markets 22 28 237 Owned Commercial Products Pipeline CGT Opportunity Products Approved Products 24 21 537 Approved ANDA’s CDMO/CMO Commercial Products Products Under Registration 51 69 40 + Pipeline Products CDMO/CMO Pipeline Products Cou
Slide 7: Key Financial Highlights – Q3 & 9M FY25
Key Financial Highlights – Q3 & 9M FY25* Income up by 157% EBIDTA up by 287% PAT after MI up by 162% Y-o-Y for 9MFY25 Y-o-Y for 9MFY25 Y-o-Y for 9MFY25 Income (INR Crs) EBITDA (INR Crs) ** PAT after MI (INR Crs) +286.9% 157.0% +162.4% 288.1 74.3 40.7 35.2% +91.8% +142.3% 106.4 112.1 29.1 17.2 15.5 7
Slide 8: Q3 & 9M FY25 Profit & Loss Account
Q3 & 9M FY25 Profit & Loss Account * Profit and Loss (INR Crs) Q3 FY25 Q3 FY24 YoY 9M FY25 9M FY24 YoY Revenue 103.0 78.7 30.9% 284.0 112.1 153.4% Other Operating Income 3.4 0.0 4.1 0.0 Total Income 106.4 78.7 35.2% 288.1 112.1 157.0% Total COGS 40.7 48.3 123.3 60.7 Gross Profit 65.7 30.4 116.2% 164
Slide 9: Update on Utilization of Funds from IPO
Update on Utilization of Funds from IPO Amount as proposed in Amount utilized as on Amount Unutilized as on Sr. No Object as per Offer Document Remarks the Offer Document December 31, 2024 December 31, 2024 Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for se
Slide 10: About Senores Pharmaceuticals Limited
About Senores Pharmaceuticals Limited Private & Confidential
Slide 11: Introduction to Senores Pharma
Introduction to Senores Pharma Brief Overview At a Glance Global Research driven Formulation Focused company engaged in developing & manufacturing of pharmaceutical products predominantly for the Regulated Markets of the US, Canada & UK across various therapeutic areas Niche Product Identification C
Slide 12: Business Segments
Business Segments 1.7% 1.5% Revenue 63.6% 29.8% 3.5% INR 284 Crs For 9MFY25 Regulated Markets Business Emerging Markets Business API Business Critical Care Injectables Business Other Operating Income Regulated Markets Business Emerging Markets Business Develop & manufacture pharmaceutical products f
Slide 13: Key Events & Milestones
Key Events & Milestones Incorporated as “Senores Consolidated presence in emerging Incorporated a wholly owned subsidiary, markets by acquiring shares in Pharmaceuticals Pvt. Ltd.” in India. Senores Pharmaceuticals Inc in the US Ratnatris Pharmaceuticals Pvt. Ltd. 2021 2017 2021 2021 2023 2023 2024
Slide 14: Key Strengths
Key Strengths Private & Confidential
Slide 15: Key Strengths of the Company
Key Strengths of the Company 1 Distinct specialty and complex product portfolio built in a short span for Regulated Markets 2 Long-term marketing arrangements with pharmaceutical companies in the Regulated Markets 3 Presence in the Emerging Markets with portfolio, including specialty and complex pro
Slide 16: Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets
1 Distinct Specialty & Complex Product Portfolio Built in a Short Span for Regulated Markets Demonstrated Capability to propel Products from Conception to Commercialization ANDA Products Product Identification Product Development Commercial Data Analysis – IQVIA, R&D to establish API Concurrent Part
Slide 17: Presence in Regulated Markets through Long-term marketing arrangements
2 Presence in Regulated Markets through Long -term marketing arrangements MARKETED PRODUCTS CDMO / CMO Business Model Business Model Identify, Develop & Commercialize specialty & complex Customized formulation, development & manufacturing niche products in mid - market range capabilities for custome
Slide 18: Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products
3 Presence in the Emerging Markets with Portfolio Including Specialty and Complex Products Special Focus Niche & Specialty patented products in the US with early launch 345 opportunity in Emerging Markets 84 South East 40+ Commonwealth of Asia Countries Sugammadex Ferric Independent Marketed States
Slide 19: Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets
Partners to Global Pharmaceutical Companies in Regulated & Emerging Markets 18
Slide 20: Strong R&D Capabilities Driving Differentiated Product Portfolio
Strong R&D Capabilities Driving Differentiated Product Portfolio R&D Site 1 - USA Identify Oral Oral ▪ Internal research ORS Injectables API Solids Liquids ▪ In-House R&D in US ▪ Information available for Controlled on subscribed Substances databases R&D Site 2 - India Team ▪ Helps in dossier ▪ 54 p
Slide 21: Accredited Manufacturing Facilities
5 Accredited Manufacturing Facilities Atlanta Facility Ahmedabad, Chhatral Facility Facility 35,205 Sq. Mtr. Total Area 2 Manufacturing Lines 12 185,300 Sq. Ft. Manufacturing Lines Total Area 4 OSD Dosage Forms 1.2 Bn units Annual Installed General Oral Beta Lactum Capacity 1 Strong Regulatory Track
Slide 22: Corporate Structure
Corporate Structure Group holding company based in India Houses Domestic Critical Care Injectables business & API business Senores Pharmaceuticals Inc. Marketing cum ANDA Havix Group Inc Ratnatris Pharmaceuticals Pvt. Ltd. Caters to Regulated Market Caters to Emerging Market Holding Company US based
Slide 23: Professional and Dedicated Management Team
6 Professional and Dedicated Management Team Swapnil Jatinbhai Shah Sanjay Shaileshbhai Majmudar Deval Rajnikant Shah Promoter & Managing Director Chairman & Non-Executive, Non- Whole-Time Director & CF O Independent Director ▪ 16+ years of experience in the pharma sector ▪ 39+ years of experience ▪
Slide 24: Growth Strategies
Growth Strategies Private & Confidential
Slide 25: Key Strategies
Key Strategies Inorganic growth Significantly enhance market through synergistic presence in North America & acquisitions other Regulated Markets Integrated approach by Launch products with the enhancing capabilities for potential of NDA approval in backward integration the US Strategic alliance for
Slide 26: Enhance Market Presence of Marketed Products in North America and Other Regulated Markets
Enhance Market Presence of Marketed Products in North America and Other Regulated Markets US accounts for 43% of the global pharma market, 56% of the regulated market & 91% Persistent drug shortage calls for an of North America Market increased supply of generic drugs Global pharma market by classif
Slide 27: Entering into Strategic Alliance for CMO/CDMO in Regulated Markets
Entering into Strategic Alliance for CMO/CDMO in Regulated Markets CDMO market growing faster than the pharma market Strategic alliance for CMO/CDMO in Regulated Markets which is growing at 7.7% US CDMO/CMO market (USD bn) The dependence on CDMO/CMO’s has increased as they offer 7.7% Appended Manufa
Slide 28: Expanding into New Regulated & Emerging Markets
Expanding into New Regulated & Emerging Markets Regulated & Emerging markets witnessing strong growth Global pharma market by classification (USD bn) Emerging pharma market by Product (2028F) Regulated pharma market by Product (2028F) Regulated Emerging Innovator Generic Generic Innovator 541.0 376.
Slide 29: Enhancing Capabilities for Backward Integration
Enhancing Capabilities for Backward Integration Indian API export market to grow at a CAGR of 8.4% Pursuing an integrated approach for greater backward integration API exports (USD bn) Setup Greenfield unit - Increase API manufacturing capacity CAGR: 8.4% Proposed from 25 MTPA to 169 MTPA 7.1 Expans
Slide 30: Industry Overview
Industry Overview Private & Confidential
Slide 31: Global Pharma Market
Global Pharma Market Global pharma market is expected to grow at …regulated market will continue to dominate the US continues to exert influence on Global pharma market 6.6% from 2023-28… global pharma market Global pharma market by product type (USD bn) Global pharma market by region (USD bn) Share
Slide 32: Regulated Pharma Market
Regulated Pharma Market Regulated markets to dominate the global pharmaceutical sector, driven by their access to a growing innovative drug market & a thriving generics market Regulated markets constitute 77% of the global North America accounts for 62% of regulated New generics and patent expiratio
Slide 33: Emerging Pharma Market
Emerging Pharma Market Emerging pharma market Overview of India pharma market Emerging markets to outpace developed ones… IPM is amongst the fastest growing in the Oral solids will dominate IPM world… Emerging pharma market size (USD bn) Indian pharma market size (USD bn) Indian pharma market by dos
Slide 34: Contact Us
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: U24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net investors@senorespharma.com +91 98
Senores Pharmaceuticals — Q3 FY25 Earnings Presentation on 6ix